|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1997-5-29
|
|
pubmed:abstractText |
The present study was undertaken to test whether the anti-viral agent foscarnet undergoes significant tubular secretion, by using probenecid, an inhibitor of the organic acid secretory pathway in the proximal segment of the nephron.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0306-5251
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
43
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
112-5
|
|
pubmed:dateRevised |
2009-10-2
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment.
|
|
pubmed:affiliation |
Department of Therapeutics, Charing Cross and Westminster Medical School, Chelsea and Westminster Hospital, London, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
